ライフサイエンスコーパス: ulcerative colitis

1 ts (16,902 with Crohn's disease, 12,597 with ulcerative colitis).

2 et engagement assessed in five patients with ulcerative colitis.

3 emission in patients with moderate-to-severe ulcerative colitis.

4 nding in mucosal biopsies from patients with ulcerative colitis.

5 I), and height, but not for Crohn disease or ulcerative colitis.

6 reported in patients with Crohn's disease or ulcerative colitis.

7 uced in colonic specimens from patients with ulcerative colitis.

8 274 paediatric patients with newly diagnosed ulcerative colitis.

9 ged about how people adjusted to living with ulcerative colitis.

10 l disease (IBD) includes Crohn's disease and ulcerative colitis.

11 one in children who are newly diagnosed with ulcerative colitis.

12 differentiated colitis, Crohn's disease, and ulcerative colitis.

13 c therapies are widely used in patients with ulcerative colitis.

14 therapy in patients with moderate-to-severe ulcerative colitis.

15 ens in children who are newly diagnosed with ulcerative colitis.

16 3% and 0.7% (odds ratio 1.75; 1.44-2.13) for ulcerative colitis.

17 se variant in ADCY7 that doubles the risk of ulcerative colitis.

18 ged 4-17 years who were newly diagnosed with ulcerative colitis.

19 to identify patients 18 years or older with ulcerative colitis.

20 human patients with Clostridium difficile or ulcerative colitis.

21 in gut mucosa among associations stronger in ulcerative colitis.

22 emission in patients with moderate to severe ulcerative colitis.

23 evalence (69 studies) of Crohn's disease and ulcerative colitis.

24 trials of tofacitinib therapy in adults with ulcerative colitis.

25 mine serves as the gold standard in treating ulcerative colitis.

26 on the risk of colorectal cancer related to ulcerative colitis.

27 ies for psoriasis, rheumatoid arthritis, and ulcerative colitis.

28 hose patients hospitalized with acute severe ulcerative colitis.

29 ransplantation and response to Infliximab in ulcerative colitis.

30 l Modification (ICD-9-CM) diagnosis code for ulcerative colitis.

31 00547659 in patients with moderate to severe ulcerative colitis.

32 animod in 197 adults with moderate-to-severe ulcerative colitis.

33 e patients had Crohn's disease, and half had ulcerative colitis.

34 ta has recently been successfully applied to ulcerative colitis.

35 ies evaluated adults with Crohn's disease or ulcerative colitis.

36 nvironmental influences, such as diabetes or ulcerative colitis.

37 omarkers associated with future diagnosis of ulcerative colitis.

38 ctivity in patients with Crohn's disease and ulcerative colitis.

39 and organoids from patients with and without ulcerative colitis.

40 cidence similar to that of Crohn disease and ulcerative colitis.

41 healing in patients with moderate-to-severe ulcerative colitis.

42 nce that could used in early phase trials of ulcerative colitis.

43 disease +11.1% [95% CI 4.8-17.8] and APC for ulcerative colitis +14.9% [10.4-19.6]) and Taiwan (APC f

44 ents with IBD and colorectal cancer (15 with ulcerative colitis, 14 with Crohn's disease, and 2 with

45 2 per 100 000 in Germany) and North America (ulcerative colitis 286 per 100 000 in the USA; Crohn's d

46 HRs were increased for patients with ulcerative colitis 4.0, 95% CI 3.4-4.7; Crohn's disease

47 Crohn's disease +4.0% [1.0-7.1] and APC for ulcerative colitis +4.8% [1.8-8.0]).

48 t reported prevalence values were in Europe (ulcerative colitis 505 per 100 000 in Norway; Crohn's di

49 ected in intestinal samples of patients with ulcerative colitis, a condition associated with increase

50 nd their metabolism is often dysregulated in ulcerative colitis, a major category of inflammatory bow

51 Guided by the Pediatric Ulcerative Colitis Activity Index (PUCAI), patients rece

52 nt (6 studies, N = 627; P = .035), Pediatric Ulcerative Colitis Activity Index score (4 studies, n =

53 Higher Pediatric Ulcerative Colitis Activity Index score and C-reactive p

54 diseases, which include Crohn's disease and ulcerative colitis, affect several million individuals w

55 Pouchitis that develops in patients with ulcerative colitis after total proctocolectomy and ileal

56 onoscopy; 322 were screened by MRC (222 with ulcerative colitis and 100 with Crohn's disease).

57 nflammatory bowel diseases (n = 119; 59 with ulcerative colitis and 60 with Crohn's disease).

58 mothers with Crohn disease (CD) and 194 with ulcerative colitis and 68,858 non-IBD mothers.

59 livered by acute CS had an increased risk of ulcerative colitis and celiac disease, whereas children

60 5, LRRK2, and MAPT for rheumatoid arthritis, ulcerative colitis and Crohn disease.

61 IBD consists of 2 subtypes: ulcerative colitis and Crohn disease.

62 To be included in the systematic review, ulcerative colitis and Crohn's disease needed to be repo

63 atory bowel disease (IBD), which consists of ulcerative colitis and Crohn's disease, are a significan

64 ammatory bowel diseases (IBD), that includes ulcerative colitis and Crohn's disease, can affect not o

65 hitecture of the inflammatory bowel diseases ulcerative colitis and Crohn's disease, we sequenced the

66 variety of clinical management scenarios for ulcerative colitis and Crohn's disease.

67 h as in inflammatory bowel disease including ulcerative colitis and Crohn's disease.

68 ing the notion of a disease continuum within ulcerative colitis and Crohn's disease.

69 th intestinal inflammatory diseases, such as ulcerative colitis and Crohn's disease.

70 bitor of MMP9, has shown promise in treating ulcerative colitis and gastric cancer.

71 ch as Crohn disease, multiple sclerosis, and ulcerative colitis and hereby elucidate the molecular me

72 80 in colonic epithelium of individuals with ulcerative colitis and in mice with experimentally induc

73 Mucosal biopsy specimens from patients with ulcerative colitis and inactive Crohn's disease have low

74 in human ileal tissues from individuals with ulcerative colitis and intestinal carcinomas, also have

75 eir beneficial use in experimental models of ulcerative colitis and lung allograft rejection led us t

76 Intestine tissues from patients with ulcerative colitis and mice with colitis have increased

77 such as psoriasis, rheumatoid arthritis, and ulcerative colitis and neurological diseases such as amy

78 2 patients with quiescent Crohn's disease or ulcerative colitis and persistent gut symptoms at 2 larg

79 The T108M polymorphism is associated with ulcerative colitis and primary sclerosing cholangitis, i

80 licylate anti-inflammatory treatment against ulcerative colitis and sodium butyrate (NaB), a short ch

81 reased compared with patients with quiescent ulcerative colitis and that colitis was attenuated in IL

82 is, psoriatic arthritis, Crohn's disease, or ulcerative colitis and who were in commercial health pla

83 hin the intestinal epithelium of humans with ulcerative colitis and wild-type (WT) mice with experime

84 of IBD (71 with Crohn's disease and 41 with ulcerative colitis) and 19 children without IBD (control

85 ith IBD (30 with Crohn's disease and 27 with ulcerative colitis) and 30 patients without IBD (control

86 with Crohn's disease (CD), 48 patients with ulcerative colitis, and 26 patients without inflammatory

87 Crohn's disease, 19/100,000 person-years for ulcerative colitis, and 5/100,000 person-years for IBD u

88 on, a collagen-induced arthritis, an induced ulcerative colitis, and an ovalbumin-induced allergic co

89 ay a major role in the immunopathogenesis of ulcerative colitis, and anti-TNF antibodies are consider

90 increased susceptibility to Crohn's disease, ulcerative colitis, and asthma.

91 iota density was reduced in Crohn's disease, ulcerative colitis, and ileal pouch-anal anastomosis.

92 disease (IBD), including Crohn's disease and ulcerative colitis, and in 2,4,6-trinitrobenzene sulfoni

93 f recovery from bone marrow transplantation, ulcerative colitis, and partial hepatectomy.

94 lved in the pathogenesis of Crohn's disease, ulcerative colitis, and pouchitis.

95 Crohn's disease, ileal Crohn's disease, and ulcerative colitis are all genetically distinct from eac

96 diseases (IBDs) such as Crohn's disease and ulcerative colitis are characterized by uncontrolled act

97 Crohn's disease and ulcerative colitis are chronic and progressive inflammat

98 Crohn's disease and ulcerative colitis are complex diseases that are heterog

99 Crohn's disease and ulcerative colitis are driven by both common and distinc

100 Crohn's disease and ulcerative colitis are heterogeneous inflammatory bowel

101 Crohn's disease and ulcerative colitis are the two forms of disorders of the

102 seases (IBDs), including Crohn's disease and ulcerative colitis, are associated with dysbiosis of the

103 el diseases (IBD), such as Crohn disease and ulcerative colitis, are chronic relapsing conditions tha

104 erative colitis) than by Crohn's disease and ulcerative colitis as currently defined.

105 markers that can predict clinical outcome in ulcerative colitis at time of diagnosis.

106 sive analysis spanning prediction tasks from ulcerative colitis, atopic dermatitis, diabetes, to many

107 Tofacitinib is effective in treatment of ulcerative colitis, but there are safety concerns.

108 of similar efficacy in treating acute severe ulcerative colitis, but there has been no comparative ev

109 ative regulator of innate immunity) in human ulcerative colitis, by comparing monozygotic twins and o

110 nflammatory bowel diseases-Crohn disease and ulcerative colitis-caused by untoward reactivity of the

111 atures for different IBD subtypes, including ulcerative colitis, colonic Crohn's disease and ileal Cr

112 uced colitis and human colonic biopsies from ulcerative colitis, compared with controls.

113 identified by GWAS, the genomic regions for ulcerative colitis, Crohn disease, and inflammatory bowe

114 Combined genomic susceptibility regions for ulcerative colitis, Crohn disease, inflammatory bowel di

115 lammatory intestinal diseases, particularly, ulcerative colitis, Crohn disease, inflammatory bowel di

116 n mucosal integrity has been associated with ulcerative colitis, Crohn's disease and potentially coul

117 tablished common susceptibility variants for ulcerative colitis, Crohn's disease, inflammatory bowel

118 y bowel disease (IBD) cohort and an in-house ulcerative colitis dataset, we shed light on the composi

119 ively, who had moderately to severely active ulcerative colitis despite previous conventional therapy

120 brilumab in patients with moderate-to-severe ulcerative colitis despite treatment with conventional t

121 ividuals vs patients with Crohn's disease or ulcerative colitis did not differ significantly after ex

122 copic, and histological data associated with ulcerative colitis disease activity in a composite index

123 y videos 1 endoscopic Mayo score (eMS) and 1 Ulcerative Colitis Endoscopic Index of Severity (UCEIS)

124 patients with moderately to severely active ulcerative colitis, etrasimod 2 mg was more effective th

125 For patients with ulcerative colitis, Eubacterium rectale and Akkermansia

126 ontaneous production of cytokines from human ulcerative colitis explants.

127 Intestinal tissues from patients with ulcerative colitis expressed significantly lower levels

128 ries, with a history (>/=3 months) of active ulcerative colitis extending more than 15 cm beyond the

129 nd perceptions of patients with acute severe ulcerative colitis following treatment with infliximab o

130 ncidence or prevalence of Crohn's disease or ulcerative colitis from 1990 or later.

131 atients aged 4-17 years with newly diagnosed ulcerative colitis from 29 centres in the USA and Canada

132 sk estimates of colorectal cancer related to ulcerative colitis from Asia vary.

133 se for terms related to colorectal cancer in ulcerative colitis from inception to July 1, 2016.

134 Conversely, patients with ulcerative colitis had an increased risk of liver diseas

135 from patients with CD and from patients with ulcerative colitis had distinct changes in DNA methylati

136 d submucosal tissue from patients with CD or ulcerative colitis had higher levels of collagens, inclu

137 lon tissues and organoids from patients with ulcerative colitis had increased levels of IL1B mRNA and

138 Ulcerative Colitis has similar presentation and behaviou

139 Previous retrospective studies of paediatric ulcerative colitis have had limited ability to describe

140 Patients with ulcerative colitis have mucosal inflammation starting in

141 Patients with Crohn's disease or ulcerative colitis have relatively high levels of stress

142 s disease (hazard ratio 2.19; 1.44-3.34) and ulcerative colitis (hazard ratio 1.63; 1.18-2.27) was si

143 r disease and its frequent complication with ulcerative colitis highlights the pathogenic role of epi

144 of CCDC88b in patients with Crohn disease or ulcerative colitis, identifying that expression correlat

145 potential efficacy as induction therapy for ulcerative colitis in a phase 2 trial.

146 with low gene dose, and the gut, developing ulcerative colitis in response to 1% dextran sulfate sod

147 follow-up, 48 men were newly diagnosed with ulcerative colitis (incidence rate (IR) = 36/100,000 per

148 Treatments for ulcerative colitis include 5-aminosalicylic acid drugs,

149 ons in adults hospitalized with acute severe ulcerative colitis included: (5) overall and comparative

150 ADT was associated with a decreased risk of ulcerative colitis (IR = 24/100,000 PY vs. IR = 50/100,0

151 Ulcerative colitis is a chronic inflammatory disease aff

152 The therapeutic armamentarium for ulcerative colitis is expanding, and the number of drugs

153 nditions in patients with Crohn's disease or ulcerative colitis is necessary for their total care and

154 ion and maintenance therapy in patients with ulcerative colitis is unknown.

155 The increased risk of colorectal cancer in ulcerative colitis is well known.

156 anti-tumor necrosis factor (TNF) therapy in ulcerative colitis, its effects on postoperative outcome

157 n sCDAI score 93 [IQR 47-156]), and 161 with ulcerative colitis (median P-SCCAI score 1 [IQR 1-3]).

158 Australia (23 with Crohn's colitis, 29 with ulcerative colitis; median age, 45.0 y; 60% male; mean I

159 uch (n = 27), normal pouch from patient with ulcerative colitis (n = 10), and normal pouch from patie

160 a diagnosis of Crohn's disease (n = 200) or ulcerative colitis (n = 199), as well as from 200 health

161 (RA, n = 229), Crohn's disease (n = 148), or ulcerative colitis (n = 36) treated with 8 different bio

162 g Cox regression separately in patients with ulcerative colitis (n = 4671), Crohn's disease (n = 3780

163 colon tissues from age-matched patients with ulcerative colitis (n=10) vs without IBD (n=8, controls)

164 ozanimod in patients with moderate-to-severe ulcerative colitis (n=179).

165 rhea (ICD) in rhesus macaques also resembles ulcerative colitis, one form of human inflammatory bowel

166 onic tissues from human subjects with active ulcerative colitis or Crohn's disease, implicating the l

167 amples from patients with Crohn's disease or ulcerative colitis or healthy individuals (controls).

168 The 14 patients with monogenic ulcerative colitis or IBD-unclassified received their di

169 rs, 69.9% had Crohn's disease, and 30.1% had ulcerative colitis or IBD-unclassified; median follow-up

170 %) had Crohn's disease, and 1451 (43.0%) had ulcerative colitis or unclassified inflammatory bowel di

171 ears old or younger and had Crohn's disease, ulcerative colitis, or IBD-unclassified with 24,543.0 pa

172 Defined as a diagnosis of Crohn's disease, ulcerative colitis, or inflammatory bowel disease unclas

173 strong colonic expression, protects against ulcerative colitis (overall P=6.89 x 10(-7), odds ratio=

174 ated macular degeneration (P=1.4 x 10(-12)), ulcerative colitis (P<1.0 x 10(-20)), type 2 diabetes (P

175 1 patients with Crohn's disease and 102 with ulcerative colitis participated.

176 of TRIM58 in myeloid cells may contribute to ulcerative colitis pathogenesis.

177 nt (rs36095412, p.R179X, genotyped in 11,148 ulcerative colitis patients and 295,446 controls, MAF=up

178 onomycin, TNF-alpha, or H(2)O(2), PBMCs from ulcerative colitis patients treated with NX-13 had decre

179 More polyps were present in the ulcerative colitis patients when compared to Crohn's dis

180 in mouse models and human primary cells from ulcerative colitis patients with effects on NF-kappaB ac

181 Host & Microbe, Leonardi et al. demonstrate ulcerative colitis patients with high Candida responded

182 In four of the five ulcerative colitis patients, biopsies taken after 7d dos

183 uded healthy volunteers, Crohn's disease and ulcerative colitis patients.

184 Genome-wide association studies in ulcerative colitis point to a role for FcgammaRIIA, a re

185 e curve (AUC) of scores from the Crohn's and Ulcerative Colitis Questionnaire (CUCQ) completed by par

186 outcomes of patients with moderate to severe ulcerative colitis receiving tofacitinib, although at an

187 icular disease, benign colonic neoplasm, and ulcerative colitis/regional enteritis were included.

188 tic architecture of Crohn's disease (CD) and ulcerative colitis remain incompletely defined.

189 the backdrop of an inflamed mucosa (e.g. in ulcerative colitis) remains exceedingly difficult.

190 hn's disease and 15 (83.3%) of 18 studies on ulcerative colitis reported stable or decreasing inciden

191 ease (rg = 0.097 +/- 0.06, P = 3.27 x 10-3), ulcerative colitis (rg = 0.11 +/- 0.04, P = 4.05 x 10-3)

192 tween PD and type 1 diabetes, Crohn disease, ulcerative colitis, rheumatoid arthritis, celiac disease

193 viduals and patients with Crohn's disease or ulcerative colitis secreted IL22, which promoted barrier

194 Finally, in patients with ulcerative colitis, SGPP2 expression was elevated in col

195 rohn's disease, colonic Crohn's disease, and ulcerative colitis) than by Crohn's disease and ulcerati

196 tify serum biomarkers of Crohn's disease and ulcerative colitis that can be detected and quantified b

197 bowel disease including Crohn's disease and ulcerative colitis, the arthritis related to anterior uv

198 In ulcerative colitis, the association was not significant.

199 Further, in patients with ulcerative colitis, the concentration of active IL-18 wa

200 With the exception of ulcerative colitis, the degree and direction of these ge

201 estigated to delineate mechanisms regulating ulcerative colitis, the role of acid ceramidase (AC) in

202 al signatures holds the promise of informing ulcerative colitis therapeutic decisions.

203 in adults with moderately to severely active ulcerative colitis to determine whether vedolizumab was

204 he response of children newly diagnosed with ulcerative colitis to standardised initial therapy and i

205 patients with moderately to severely active ulcerative colitis, tofacitinib was more effective as in

206 ide genetic correlation (rG) between PSC and ulcerative colitis (UC) (rG = 0.29) was significantly gr

207 odels for diagnosis of Crohn disease (CD) or ulcerative colitis (UC) among men and women aged 18-81 y

208 of 2017, we identified 323 incident cases of ulcerative colitis (UC) and 108 incident cases of Crohn'

209 AIMS: The inflammatory bowel diseases (IBD) ulcerative colitis (UC) and Crohn's disease (CD) cause s

210 al tract of uncertain origin, which includes ulcerative colitis (UC) and Crohn's disease (CD).

211 ase (PIBD), comprising Crohn's disease (CD), ulcerative colitis (UC) and inflammatory bowel disease u

212 sylation is likely impaired in patients with ulcerative colitis (UC) and renders UC-HMA mice more sus

213 owel disease (IBD), Crohn's disease (CD) and ulcerative colitis (UC) and to compare the occurrence of

214 ng disease course and response to therapy in ulcerative colitis (UC) are not well understood.

215 etter understanding of prognostic factors in ulcerative colitis (UC) could improve patient management

216 Patients with ulcerative colitis (UC) experience periods of recurring

217 Although Crohn's disease (CD) and ulcerative colitis (UC) have been considered as disorder

218 s, incidence rates of Crohn disease (CD) and ulcerative colitis (UC) have been increased in epidemiol

219 Most patients with ulcerative colitis (UC) have mild-to-moderate disease ac

220 hat affect risk for Crohn's disease (CD) and ulcerative colitis (UC) in a case-only study of patients

221 ered 6-shogaol and its effectiveness against ulcerative colitis (UC) in a mouse model.

222 Incidence of ulcerative colitis (UC) in elderly population is increas

223 rrelated with development and progression of ulcerative colitis (UC) in human patients.

224 Ulcerative colitis (UC) is a chronic inflammatory bowel

225 Ulcerative colitis (UC) is a risk factor for colorectal

226 Ulcerative colitis (UC) is one of the main types of chro

227 Endoscopic disease activity scoring in ulcerative colitis (UC) is useful in clinical practice b

228 The odds of having ulcerative colitis (UC) or Crohn disease (CD) were eleva

229 mparisons of biologic treatment outcomes for ulcerative colitis (UC) or Crohn's disease (CD) patients

230 quencing, and measured the GMSI in 77 CD and ulcerative colitis (UC) patients (24 low and 53 normal G

231 specimens from 16 Crohn's disease (CD) and 6 ulcerative colitis (UC) patients and compared them to sa

232 d in colonic biopsies and blood samples from ulcerative colitis (UC) patients compared with healthy c

233 ive models of disease burden at diagnosis in ulcerative colitis (UC) patients for future use in popul

234 ospective study with Crohn's disease (CD) or ulcerative colitis (UC) patients initiating anti-integri

235 Similarly, ulcerative colitis (UC) patients responsive to fecal mic

236 ptom profiles among Crohn's disease (CD) and ulcerative colitis (UC) patients, respectively.

237 A subset of patients with ulcerative colitis (UC) present with, or progress to, mo

238 ndrome (IBS) is more common in patients with ulcerative colitis (UC) than expected.

239 f human colonic CD8(+) T cells in health and ulcerative colitis (UC) using single-cell transcriptomic

240 esevoirs) in colectomy-treated patients with ulcerative colitis (UC) versus controls (familial adenom

241 s in inflammatory responses of patients with ulcerative colitis (UC) vs Crohn's disease (CD).

242 and TJP1) and IBD, Crohn's disease (CD), or ulcerative colitis (UC) were investigated.

243 stem was queried for hospital admissions for ulcerative colitis (UC) with concurrent colectomy and Cr

244 As is known, ulcerative colitis (UC), a chronic inflammatory disease,

245 c basis between CC and Crohn's disease (CD), ulcerative colitis (UC), and celiac disease.

246 main forms of irritable bowel disease (IBD), ulcerative colitis (UC), and Crohn's disease (CD).

247 nal ACE2 expression in Crohn's disease (CD), ulcerative colitis (UC), and non-inflammatory bowel dise

248 The ST2/IL-33 pathway has been related to ulcerative colitis (UC), and soluble ST2 (sST2), to dise

249 es (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), are complex chronic inflammator

250 BDs), which include Crohn's disease (CD) and ulcerative colitis (UC), are multifactorial chronic cond

251 with inflammatory bowel diseases, including ulcerative colitis (UC), but the causality and mechanism

252 in has shown to be elevated in patients with ulcerative colitis (UC), Crohn's disease (CD) and colore

253 nal inflammation in Crohn's disease (CD) and ulcerative colitis (UC), in humans.

254 cohort study with 21 patients suffering from ulcerative colitis (UC), in which first-time treatment w

255 se (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), is a disease associated with dy

256 The economic burden of ulcerative colitis (UC), specifically related to indirec

257 transabdominal minimal invasive approach in ulcerative colitis (UC), using the comprehensive complic

258 ype 2 immune response in the pathogenesis of ulcerative colitis (UC)-few data are available from trea

259 (FMT) can induce remission in patients with ulcerative colitis (UC).

260 tracheobronchitis is a rare complication of ulcerative colitis (UC).

261 n a distant background of surgically managed ulcerative colitis (UC).

262 large randomized controlled trial of FMT for ulcerative colitis (UC).

263 tudies (GWAS) have revealed risk alleles for ulcerative colitis (UC).

264 sociated with the intestinal disease such as ulcerative colitis (UC).

265 with two subtypes, Crohn's disease (CD) and ulcerative colitis (UC).

266 has demonstrated efficacy in treating active ulcerative colitis (UC).

267 ncommon but life-threatening complication of ulcerative colitis (UC).

268 nosed with Crohn's disease (CD) and 361 with ulcerative colitis (UC).

269 signalling pathway has been associated with ulcerative colitis (UC).

270 nastomosis (IRA) failure after colectomy for ulcerative colitis (UC).

271 -resistant colonic Crohn's disease (cCD) and ulcerative colitis (UC).

272 ving pathways) contribute to pathogenesis of ulcerative colitis (UC).

273 osal inflammatory cytokines in patients with ulcerative colitis (UC).

274 n the intestinal microbiota of patients with ulcerative colitis (UC).

275 risk of developing Crohn's disease (CD) and ulcerative colitis (UC).

276 patients with moderately to severely active ulcerative colitis (UC).

277 ains histologic improvement in patients with ulcerative colitis (UC).

278 colonic mucosa [50 Crohn's disease (CD); 80 ulcerative colitis (UC); 31 controls].

279 om patients with Crohn's disease (n = 61) or ulcerative colitis (UC, n = 74) or from patients without

280 h IBD (43 with Crohn's disease [CD], 23 with ulcerative colitis [UC]), and 30 children without IBD (c

281 ors and risk of IBD (Crohn's disease [CD] or ulcerative colitis [UC]).

282 535 consecutive patients with IBD (211 with ulcerative colitis [UC], 234 with Crohn's disease [CD];

283 roscopy in 110 consecutive subjects (31 with ulcerative colitis [UC], 57 with Crohn's disease [CD], a

284 h IBD (11 with Crohn's disease [CD], 13 with ulcerative colitis [UC], mean age 45 years [range 19-90]

285 d in early clinical studies for treatment of ulcerative colitis, using conditions that mimic the huma

286 Ulcerative colitis usually presents with bloody diarrhoe

287 patients with moderately to severely active ulcerative colitis, vedolizumab was superior to adalimum

288 lammatory polyps, family history of CRC, and ulcerative colitis versus Crohn's disease was considered

289 found no difference between individuals with ulcerative colitis vs Crohn's disease.

290 of IL19 in biopsies of patients with active ulcerative colitis was increased compared with patients

291 of colorectal cancer in Asian patients with ulcerative colitis was similar to recent estimates in Eu

292 Former smokers with ulcerative colitis were at increased risk of colectomy (

293 Treatment naive-patients with ulcerative colitis were included at time of initial diag

294 dred seventy patients with steroid-resistant ulcerative colitis were randomised to either infliximab

295 variate, Crohn's disease and no IBD (both vs ulcerative colitis) were associated with a lower risk of

296 R, $87335-$126541]), and total colectomy for ulcerative colitis (WIQR, $24497; median, $34910 [IQR, $

297 miRNA signature identified in mice predicted ulcerative colitis with 83.3% accuracy.

298 sis included a total of 31 287 patients with ulcerative colitis with a total of 293 reported colorect

299 ntified patients who received a diagnosis of ulcerative colitis within 5 years with an AUROC of only

300 nd Work Productivity and Activity Impairment-Ulcerative Colitis [WPAI-UC] questionnaire).